South Korea · Delayed Price · Currency is KRW NeoImmuneTech Statistics
Total Valuation
NeoImmuneTech has a market cap or net worth of KRW 174.70 billion. The enterprise value is 124.37 billion.
| Market Cap | 174.70B |
| Enterprise Value | 124.37B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoImmuneTech has 98.87 million shares outstanding. The number of shares has increased by 35.30% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 98.87M |
| Shares Change (YoY) | +35.30% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | n/a |
| Float | 92.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 287.07 |
| PB Ratio | 3.22 |
| P/TBV Ratio | 4.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 204.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.65, with a Debt / Equity ratio of 0.20.
| Current Ratio | 2.65 |
| Quick Ratio | 2.54 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.44 |
| Interest Coverage | -9.68 |
Financial Efficiency
Return on equity (ROE) is -71.12% and return on invested capital (ROIC) is -26.89%.
| Return on Equity (ROE) | -71.12% |
| Return on Assets (ROA) | -21.35% |
| Return on Invested Capital (ROIC) | -26.89% |
| Return on Capital Employed (ROCE) | -41.84% |
| Weighted Average Cost of Capital (WACC) | 6.55% |
| Revenue Per Employee | 11.70M |
| Profits Per Employee | -596.89M |
| Employee Count | 52 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -38.73M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.95% in the last 52 weeks. The beta is 0.29, so NeoImmuneTech's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -71.95% |
| 50-Day Moving Average | 2,525.64 |
| 200-Day Moving Average | 3,561.34 |
| Relative Strength Index (RSI) | 36.67 |
| Average Volume (20 Days) | 979,559 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeoImmuneTech had revenue of KRW 608.57 million and -31.04 billion in losses. Loss per share was -232.79.
| Revenue | 608.57M |
| Gross Profit | 608.57M |
| Operating Income | -23.48B |
| Pretax Income | -31.08B |
| Net Income | -31.04B |
| EBITDA | -20.35B |
| EBIT | -23.48B |
| Loss Per Share | -232.79 |
Balance Sheet
The company has 57.83 billion in cash and 10.91 billion in debt, with a net cash position of 46.92 billion or 474.59 per share.
| Cash & Cash Equivalents | 57.83B |
| Total Debt | 10.91B |
| Net Cash | 46.92B |
| Net Cash Per Share | 474.59 |
| Equity (Book Value) | 54.32B |
| Book Value Per Share | 336.89 |
| Working Capital | 37.70B |
Cash Flow
In the last 12 months, operating cash flow was -24.75 billion and capital expenditures 108.56 million, giving a free cash flow of -24.64 billion.
| Operating Cash Flow | -24.75B |
| Capital Expenditures | 108.56M |
| Depreciation & Amortization | 3.12B |
| Net Borrowing | -727.95M |
| Free Cash Flow | -24.64B |
| FCF Per Share | -249.20 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -3,857.66% |
| Pretax Margin | -5,106.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NeoImmuneTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.30% |
| Shareholder Yield | -35.30% |
| Earnings Yield | -17.77% |
| FCF Yield | -14.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 15, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 15, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
NeoImmuneTech has an Altman Z-Score of 3.59 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.59 |
| Piotroski F-Score | 3 |